Central nervous system relapse in adults with acute lymphoblastic leukemia

Usha R. Surapaneni, Jorge E. Cortes, Deborah Thomas, Susan O'Brien, Francis J. Giles, Charles Koller, Stefan Faderl, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) in adults is considered a poor prognostic feature. Few reports have analyzed this issue. The objective of this study was to analyze the experience with CNS recurrence in adult patients with ALL. METHODS. Between December 1982 and April 2000, the records of 527 consecutive, newly diagnosed patients with ALL who were treated at the M. D. Anderson Cancer Center were reviewed. Patients were treated with one of two published regimens: vincristine, doxorubicin, and dexamethasone (VAD; n = 237 patients) or hyper-fractionated cyclophosphamide plus VAD (hyper-CVAD) (n = 290 patients). Among 439 patients (83%) who achieved complete remission (CR), 32 patients (7%) had a CNS recurrence. All patients had received CNS prophylaxis tailored to the risk of CNS recurrence with systemic chemotherapy with or without intrathecal (IT) chemotherapy; none received cranial radiotherapy for prophylaxis. The records of these patients were reviewed. RESULTS. The median age at the time of diagnosis was 33 years. The median CR duration prior to CNS recurrence was 36 weeks (range, 2-185 weeks). Three groups were identified: 1) patients with an isolated CNS recurrence (n = 17 patients), 2) patients with CNS recurrences after bone marrow (BM) recurrence (n = 8 patients), and 3) patients with simultaneous CNS and BM recurrences (n = 7 patients). IT chemotherapy was effective in achieving a CNS CR in 30 patients (94%), but 10 patients (31%) had a second CNS recurrence. The median survival from CNS recurrence was 6 months; 28% of patients were alive at 1 year, and 6% of patients were alive at 4 years. CONCLUSIONS. Adults with ALL and CNS recurrences have a poor prognosis despite effective IT chemotherapy. Future studies should investigate better approaches in the treatment of these patients to improve their long-term survival. Effective CNS prophylaxis remains the single best approach for treating patients with CNS leukemia.

Original languageEnglish (US)
Pages (from-to)773-779
Number of pages7
JournalCancer
Volume94
Issue number3
DOIs
StatePublished - Feb 1 2002
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Central Nervous System
Recurrence
Drug Therapy
Bone Marrow
Survival
Vincristine

Keywords

  • Acute lymphoblastic leukemia
  • Bone marrow
  • Central nervous system
  • Peripheral blood
  • Relapse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Surapaneni, U. R., Cortes, J. E., Thomas, D., O'Brien, S., Giles, F. J., Koller, C., ... Kantarjian, H. (2002). Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer, 94(3), 773-779. https://doi.org/10.1002/cncr.10265

Central nervous system relapse in adults with acute lymphoblastic leukemia. / Surapaneni, Usha R.; Cortes, Jorge E.; Thomas, Deborah; O'Brien, Susan; Giles, Francis J.; Koller, Charles; Faderl, Stefan; Kantarjian, Hagop.

In: Cancer, Vol. 94, No. 3, 01.02.2002, p. 773-779.

Research output: Contribution to journalArticle

Surapaneni, UR, Cortes, JE, Thomas, D, O'Brien, S, Giles, FJ, Koller, C, Faderl, S & Kantarjian, H 2002, 'Central nervous system relapse in adults with acute lymphoblastic leukemia', Cancer, vol. 94, no. 3, pp. 773-779. https://doi.org/10.1002/cncr.10265
Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002 Feb 1;94(3):773-779. https://doi.org/10.1002/cncr.10265
Surapaneni, Usha R. ; Cortes, Jorge E. ; Thomas, Deborah ; O'Brien, Susan ; Giles, Francis J. ; Koller, Charles ; Faderl, Stefan ; Kantarjian, Hagop. / Central nervous system relapse in adults with acute lymphoblastic leukemia. In: Cancer. 2002 ; Vol. 94, No. 3. pp. 773-779.
@article{89d7b1ad54fc429184a9e620e189924b,
title = "Central nervous system relapse in adults with acute lymphoblastic leukemia",
abstract = "BACKGROUND. Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) in adults is considered a poor prognostic feature. Few reports have analyzed this issue. The objective of this study was to analyze the experience with CNS recurrence in adult patients with ALL. METHODS. Between December 1982 and April 2000, the records of 527 consecutive, newly diagnosed patients with ALL who were treated at the M. D. Anderson Cancer Center were reviewed. Patients were treated with one of two published regimens: vincristine, doxorubicin, and dexamethasone (VAD; n = 237 patients) or hyper-fractionated cyclophosphamide plus VAD (hyper-CVAD) (n = 290 patients). Among 439 patients (83{\%}) who achieved complete remission (CR), 32 patients (7{\%}) had a CNS recurrence. All patients had received CNS prophylaxis tailored to the risk of CNS recurrence with systemic chemotherapy with or without intrathecal (IT) chemotherapy; none received cranial radiotherapy for prophylaxis. The records of these patients were reviewed. RESULTS. The median age at the time of diagnosis was 33 years. The median CR duration prior to CNS recurrence was 36 weeks (range, 2-185 weeks). Three groups were identified: 1) patients with an isolated CNS recurrence (n = 17 patients), 2) patients with CNS recurrences after bone marrow (BM) recurrence (n = 8 patients), and 3) patients with simultaneous CNS and BM recurrences (n = 7 patients). IT chemotherapy was effective in achieving a CNS CR in 30 patients (94{\%}), but 10 patients (31{\%}) had a second CNS recurrence. The median survival from CNS recurrence was 6 months; 28{\%} of patients were alive at 1 year, and 6{\%} of patients were alive at 4 years. CONCLUSIONS. Adults with ALL and CNS recurrences have a poor prognosis despite effective IT chemotherapy. Future studies should investigate better approaches in the treatment of these patients to improve their long-term survival. Effective CNS prophylaxis remains the single best approach for treating patients with CNS leukemia.",
keywords = "Acute lymphoblastic leukemia, Bone marrow, Central nervous system, Peripheral blood, Relapse",
author = "Surapaneni, {Usha R.} and Cortes, {Jorge E.} and Deborah Thomas and Susan O'Brien and Giles, {Francis J.} and Charles Koller and Stefan Faderl and Hagop Kantarjian",
year = "2002",
month = "2",
day = "1",
doi = "10.1002/cncr.10265",
language = "English (US)",
volume = "94",
pages = "773--779",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Central nervous system relapse in adults with acute lymphoblastic leukemia

AU - Surapaneni, Usha R.

AU - Cortes, Jorge E.

AU - Thomas, Deborah

AU - O'Brien, Susan

AU - Giles, Francis J.

AU - Koller, Charles

AU - Faderl, Stefan

AU - Kantarjian, Hagop

PY - 2002/2/1

Y1 - 2002/2/1

N2 - BACKGROUND. Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) in adults is considered a poor prognostic feature. Few reports have analyzed this issue. The objective of this study was to analyze the experience with CNS recurrence in adult patients with ALL. METHODS. Between December 1982 and April 2000, the records of 527 consecutive, newly diagnosed patients with ALL who were treated at the M. D. Anderson Cancer Center were reviewed. Patients were treated with one of two published regimens: vincristine, doxorubicin, and dexamethasone (VAD; n = 237 patients) or hyper-fractionated cyclophosphamide plus VAD (hyper-CVAD) (n = 290 patients). Among 439 patients (83%) who achieved complete remission (CR), 32 patients (7%) had a CNS recurrence. All patients had received CNS prophylaxis tailored to the risk of CNS recurrence with systemic chemotherapy with or without intrathecal (IT) chemotherapy; none received cranial radiotherapy for prophylaxis. The records of these patients were reviewed. RESULTS. The median age at the time of diagnosis was 33 years. The median CR duration prior to CNS recurrence was 36 weeks (range, 2-185 weeks). Three groups were identified: 1) patients with an isolated CNS recurrence (n = 17 patients), 2) patients with CNS recurrences after bone marrow (BM) recurrence (n = 8 patients), and 3) patients with simultaneous CNS and BM recurrences (n = 7 patients). IT chemotherapy was effective in achieving a CNS CR in 30 patients (94%), but 10 patients (31%) had a second CNS recurrence. The median survival from CNS recurrence was 6 months; 28% of patients were alive at 1 year, and 6% of patients were alive at 4 years. CONCLUSIONS. Adults with ALL and CNS recurrences have a poor prognosis despite effective IT chemotherapy. Future studies should investigate better approaches in the treatment of these patients to improve their long-term survival. Effective CNS prophylaxis remains the single best approach for treating patients with CNS leukemia.

AB - BACKGROUND. Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) in adults is considered a poor prognostic feature. Few reports have analyzed this issue. The objective of this study was to analyze the experience with CNS recurrence in adult patients with ALL. METHODS. Between December 1982 and April 2000, the records of 527 consecutive, newly diagnosed patients with ALL who were treated at the M. D. Anderson Cancer Center were reviewed. Patients were treated with one of two published regimens: vincristine, doxorubicin, and dexamethasone (VAD; n = 237 patients) or hyper-fractionated cyclophosphamide plus VAD (hyper-CVAD) (n = 290 patients). Among 439 patients (83%) who achieved complete remission (CR), 32 patients (7%) had a CNS recurrence. All patients had received CNS prophylaxis tailored to the risk of CNS recurrence with systemic chemotherapy with or without intrathecal (IT) chemotherapy; none received cranial radiotherapy for prophylaxis. The records of these patients were reviewed. RESULTS. The median age at the time of diagnosis was 33 years. The median CR duration prior to CNS recurrence was 36 weeks (range, 2-185 weeks). Three groups were identified: 1) patients with an isolated CNS recurrence (n = 17 patients), 2) patients with CNS recurrences after bone marrow (BM) recurrence (n = 8 patients), and 3) patients with simultaneous CNS and BM recurrences (n = 7 patients). IT chemotherapy was effective in achieving a CNS CR in 30 patients (94%), but 10 patients (31%) had a second CNS recurrence. The median survival from CNS recurrence was 6 months; 28% of patients were alive at 1 year, and 6% of patients were alive at 4 years. CONCLUSIONS. Adults with ALL and CNS recurrences have a poor prognosis despite effective IT chemotherapy. Future studies should investigate better approaches in the treatment of these patients to improve their long-term survival. Effective CNS prophylaxis remains the single best approach for treating patients with CNS leukemia.

KW - Acute lymphoblastic leukemia

KW - Bone marrow

KW - Central nervous system

KW - Peripheral blood

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=0036469111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036469111&partnerID=8YFLogxK

U2 - 10.1002/cncr.10265

DO - 10.1002/cncr.10265

M3 - Article

C2 - 11857312

AN - SCOPUS:0036469111

VL - 94

SP - 773

EP - 779

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -